A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors
Completed · Phase 1
Conditions studied: Neoplasm
In brief
This study will test a new cancer medication to determine if this medication will block blood supply to a tumor and decrease growth of a tumor. This study will also define the safety profile and define the safest dose of this new medication for people who have cancer.
Key facts
- Study ID
- NCT01105533
- Run by
- Pfizer
- People needed
- 46
- Starts
- 2006-05-01
- Expected to finish
- 2011-09-01
- Last updated by the study team
- 2013-03-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically confirmed advanced solid tumors un-responsive to currently available therapies or for which there is no standard therapy.
- At least 1 measurable disease site as defined by Response Evaluation Criterion in Solid Tumors [RECIST].
- Adequate bone marrow, liver function and renal function as defined by protocol.
- Blood pressure Requirements During dose escalation - no evidence of pre-existing hypertension and no antihypertensive medications at baseline.
- During dose expansion - patient's whose hypertension is controlled by antihypertensive therapy.
You may not qualify if…
- Chemotherapy, radiotherapy or any investigational therapy within 4 weeks of study entry
- Current use or anticipated need for drugs that are known CYP34 inhibitors or inducers.
- Patients with carcinomatous meningitis or un-treated brain metastases.
- Any acute cardiovascular incident within the past 12 months.
- Patients with active gastrointestinal bleeding or significant gastrointestinal abnormalities as defined by protocol
- Patients with no evidence of the following for 5 years: malignancy or metastatic disease of skin cancer (except melanoma), in situ cervical cancer or breast cancer or T1C prostate cancer.
Where it is running
- Pfizer Investigational Site — Detroit, Michigan, United States
- Pfizer Investigational Site — Detroit, Michigan, United States
- Pfizer Investigational Site — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.